Clinical commissioning policy: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

Document first published:
Page updated:
Topic:
Publication type:
,

Osilodrostat phosphate is not recommended to be available as a routinely commissioned treatment for adult patients with endogenous Cushing’s Syndrome.

Document

Clinical commissioning policy: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

Clinical commissioning policy: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

  • PDF
  • 148 KB
  • 5 pages

Summary

Published 16 July 2026.

Document

CPAG summary report: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

CPAG summary report: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

  • PDF
  • 766 KB
  • 54 pages

Summary

PDF format. Published 26 August 2026.

Document

Clinical panel report (April 2024): Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

Clinical panel report (April 2024): Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

  • PDF
  • 166 KB
  • 6 pages

Summary

PDF format. Published 26 August 2026.

Document

Clinical panel report (June 2024): Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

Clinical panel report (June 2024): Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

  • PDF
  • 100 KB
  • 2 pages

Summary

PDF format. Published 26 August 2026.

Document

Evidence review A: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome – excluding Cushing's disease

Evidence review A: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome – excluding Cushing's disease

  • PDF
  • 929 KB
  • 91 pages

Summary

PDF format. Published 26 August 2026.

Document

Evidence review B: Osilodrostat phosphate for adult patients with Cushing's disease

Evidence review B: Osilodrostat phosphate for adult patients with Cushing's disease

  • PDF
  • 1 MB
  • 136 pages

Summary

PDF format. Published 26 August 2026.

Document

Engagement report: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

Engagement report: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

  • PDF
  • 195 KB
  • 4 pages

Summary

PDF format. Published 26 August 2026.

Document

Public health evidence report: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

Public health evidence report: Osilodrostat phosphate for adult patients with endogenous Cushing’s syndrome

  • PDF
  • 125 KB
  • 3 pages

Summary

PDF format. Published 26 August 2026.